-
1
-
-
33748184511
-
American Chemical Society 215th National Meeting (Part VI). ATP site-directed kinase inhibitors, Dallas, TX, USA
-
March 29-April 02
-
American Chemical Society 215th National Meeting (Part VI). ATP site-directed kinase inhibitors, Dallas, TX, USA. Denny WA IDDB MEETING REPORT 1998 March 29-April 02
-
(1998)
IDDB Meeting Report
-
-
Denny, W.A.1
-
2
-
-
13144266690
-
Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor
-
Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ et al PROC NATL ACAD SCI USA 1998 95 20 12022-12027 This study demonstrated the mechanism of action of irreversible inhibitors of ErbB-1 and ErbB-2 receptors at the ATP binding site.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, Issue.20
, pp. 12022-12027
-
-
Fry, D.W.1
Bridges, A.J.2
Denny, W.A.3
Doherty, A.4
Greis, K.D.5
Hicks, J.L.6
Hook, K.E.7
Keller, P.R.8
Leopold, W.R.9
Loo, J.A.10
McNamara, D.J.11
-
3
-
-
0031731295
-
Tyrosine kinase inhibitors in cancer treatment (Part II)
-
Tyrosine kinase inhibitors in cancer treatment (Part II). Traxler P EXP OPIN THER PAT 1998 8 12 1599-1625
-
(1998)
Exp Opin Ther Pat
, vol.8-12
, pp. 1599-1625
-
-
Traxler, P.1
-
4
-
-
0033987746
-
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
-
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. Druker BJ, Lydon NB J CLIN INVEST 2000 105 1 3-7
-
(2000)
J Clin Invest
, vol.105
, Issue.1
, pp. 3-7
-
-
Druker, B.J.1
Lydon, N.B.2
-
5
-
-
33748127293
-
Drug development pipeline: PD-0183805
-
Warner Lambert Co January 24
-
Drug development pipeline: PD-0183805. Warner Lambert Co COMPANY COMMUNICATION 2000 January 24
-
(2000)
Company Communication
-
-
-
6
-
-
84898689516
-
Gene expression profiling of anti-tumor efficacy of the irreversable EGFR/ERBB family inhibitor Cl-1033 in vivo
-
Abs 3077
-
Gene expression profiling of anti-tumor efficacy of the irreversable EGFR/ERBB family inhibitor Cl-1033 in vivo. Christensen JG, Messamore J, Ferguson E, Jatkoe TA, Vincent PW, Leopold WR, Madore SJ, Elliot WL PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 3077
-
(2000)
Proc Annu Meet Am Assoc Cancer Res
, vol.41
-
-
Christensen, J.G.1
Messamore, J.2
Ferguson, E.3
Jatkoe, T.A.4
Vincent, P.W.5
Leopold, W.R.6
Madore, S.J.7
Elliot, W.L.8
-
7
-
-
0000742694
-
Investigation of the effects of the tyrosine kinase (TK) inhibitor Cl-1033 (PD0183805) against human tumor specimens taken directly from patients
-
Abs 3078
-
Investigation of the effects of the tyrosine kinase (TK) inhibitor Cl-1033 (PD0183805) against human tumor specimens taken directly from patients. Medina L, Gomez L, Cema C, Kraker A, Yochomowitz M, Weitman S PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 3078
-
(2000)
Proc Annu Meet Am Assoc Cancer Res
, vol.41
-
-
Medina, L.1
Gomez, L.2
Cema, C.3
Kraker, A.4
Yochomowitz, M.5
Weitman, S.6
-
8
-
-
0011873428
-
Irreversible inhibition of ErbB receptor family in rats results in epithelial atrophy and ulcerative dermatitis
-
Abs 3142
-
Irreversible inhibition of ErbB receptor family in rats results in epithelial atrophy and ulcerative dermatitis. Breider MA PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 3142
-
(2000)
Proc Annu Meet Am Assoc Cancer Res
, vol.41
-
-
Breider, M.A.1
-
9
-
-
33748210507
-
Inhibition of ErbB family receptors by Cl-1033 enhances the cytotoxicity of gemcitabine via modulation of AM and MAP kinases
-
Abs 1533
-
Inhibition of ErbB family receptors by Cl-1033 enhances the cytotoxicity of gemcitabine via modulation of AM and MAP kinases. Nelson JM, Fry DW PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 1533
-
(2000)
Proc Annu Meet Am Assoc Cancer Res
, vol.41
-
-
Nelson, J.M.1
Fry, D.W.2
-
10
-
-
33748135745
-
Synergy between the topoisomerase inhibitor SN-38 and the Her tyrosine kinase inhibitor Cl-1033
-
Abs 925
-
Synergy between the topoisomerase inhibitor SN-38 and the Her tyrosine kinase inhibitor Cl-1033. Erlichman C, Boemer S, Wang XY, James CD, Kaufmann SH PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 925
-
(2000)
Proc Annu Meet Am Assoc Cancer Res
, vol.41
-
-
Erlichman, C.1
Boemer, S.2
Wang, X.Y.3
James, C.D.4
Kaufmann, S.H.5
-
11
-
-
33748179079
-
American Association for Cancer Research 91st Annual Meeting (Part XX), small molecule inhibitors of cell signaling, San Francisco, CA, USA
-
April 01-05
-
American Association for Cancer Research 91st Annual Meeting (Part XX), Small Molecule Inhibitors of Cell Signaling, San Francisco, CA, USA. Denny WA IDDB MEETING REPORT 2000 April 01-05
-
(2000)
IDDB Meeting Report
-
-
Denny, W.A.1
-
12
-
-
0034611617
-
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
-
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. Smail JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Hollis Showalter HD, Vincent PW, Elliot WL, Denny WA J MED CHEM 2000 43 7 1380-1397
-
(2000)
J Med Chem
, vol.43
, Issue.7
, pp. 1380-1397
-
-
Smail, J.B.1
Rewcastle, G.W.2
Loo, J.A.3
Greis, K.D.4
Chan, O.H.5
Reyner, E.L.6
Lipka, E.7
Hollis Showalter, H.D.8
Vincent, P.W.9
Elliot, W.L.10
Denny, W.A.11
-
13
-
-
33748152520
-
27th National Medicinal Chemistry Symposium, Kansas City, MO, USA
-
June 13-17
-
27th National Medicinal Chemistry Symposium, Kansas City, MO, USA. Enuezie C IDDB MEETING REPORT 2000 June 13-17
-
(2000)
IDDB Meeting Report
-
-
Enuezie, C.1
-
14
-
-
0005377698
-
Cl-1033: An irreversible inhibitor of the ErbB family of oncogenes
-
Cl-1033: An irreversible inhibitor of the ErbB family of oncogenes. Bridges AJ NAT MED CHEM SYMP 2000 S-04
-
(2000)
Nat Med Chem Symp
-
-
Bridges, A.J.1
-
15
-
-
0035116613
-
Receptor tyrosine kinase inhibitors
-
Receptor tyrosine kinase inhibitors. Haluska P, Adjei AA CURR OPIN INVEST DRUGS 2001 2 2 280-286
-
(2001)
Curr Opin Invest Drugs
, vol.2
, Issue.2
, pp. 280-286
-
-
Haluska, P.1
Adjei, A.A.2
-
16
-
-
0008639966
-
Wall street analysts meeting
-
Pfizer Inc December 11
-
Wall Street analysts meeting. Pfizer Inc COMPANY COMMUNICATION 2000 December 11
-
(2000)
Company Communication
-
-
-
17
-
-
0001357911
-
A phase I and pharmacokinetic study of Cl-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors
-
Abs 283
-
A phase I and pharmacokinetic study of Cl-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Garrison MA, Tolcher A, McCreery H, Rowinsky EK, Schott A, Mace J, Drengler R, Patnaik A, Denis L, Lenehan P, Eiseman I et al PROC AM SOC CLIN ONCOL 2001 20 Abs 283
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Garrison, M.A.1
Tolcher, A.2
McCreery, H.3
Rowinsky, E.K.4
Schott, A.5
Mace, J.6
Drengler, R.7
Patnaik, A.8
Denis, L.9
Lenehan, P.10
Eiseman, I.11
-
18
-
-
0002353789
-
A phase I clinical and biomarker study of Cl-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors
-
Abs 324
-
A phase I clinical and biomarker study of Cl-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors. Shin DM, Nemunaitis J, Zinner RG, Donato NJ, Shin HC, Myers JN, Zhang PS, Zentgraf RT, Khuri FR, Glisson BS, Eiseman I et al PROC AM SOC CLIN ONCOL 2001 20 Abs 324
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Shin, D.M.1
Nemunaitis, J.2
Zinner, R.G.3
Donato, N.J.4
Shin, H.C.5
Myers, J.N.6
Zhang, P.S.7
Zentgraf, R.T.8
Khuri, F.R.9
Glisson, B.S.10
Eiseman, I.11
-
19
-
-
0035253847
-
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor
-
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL et al J MED CHEM 2001 44 3 429-440
-
(2001)
J Med Chem
, vol.44
, Issue.3
, pp. 429-440
-
-
Smaill, J.B.1
Showalter, H.D.2
Zhou, H.3
Bridges, A.J.4
McNamara, D.J.5
Fry, D.W.6
Nelson, J.M.7
Sherwood, V.8
Vincent, P.W.9
Roberts, B.J.10
Elliott, W.L.11
-
20
-
-
33748125992
-
American Society of Clinical Oncology - 37th Annual Meeting (Part IX), San Francisco, CA, USA
-
May 12-15
-
American Society of Clinical Oncology - 37th Annual Meeting (Part IX), San Francisco, CA, USA. Boven E IDDB MEETING REPORT 2001 May 12-15
-
(2001)
IDDB Meeting Report
-
-
Boven, E.1
-
21
-
-
0003861630
-
American Society of Clinical Oncology - 37th Annual Meeting (Part XI), San Francisco, CA, USA
-
May 12-15
-
American Society of Clinical Oncology - 37th Annual Meeting (Part XI), San Francisco, CA, USA. Morse M IDDB MEETING REPORT 2001 May 12-15
-
(2001)
IDDB Meeting Report
-
-
Morse, M.1
-
22
-
-
33748207522
-
Lung Cancer - Seventh Central European Conference, New Therapeutic Strategies, Prague, Czech Republic
-
June 03-06
-
Lung Cancer - Seventh Central European Conference, New Therapeutic Strategies, Prague, Czech Republic. Awada A IDDB MEETING REPORT 2001 June 03-06
-
(2001)
IDDB Meeting Report
-
-
Awada, A.1
-
23
-
-
0003305567
-
Healthcare: Pharmaceuticals: Pharmaceutical Industry review
-
September 27
-
Healthcare: Pharmaceuticals: Pharmaceutical Industry Review. Rubin J, Yu N, Sone T MORGAN STANLEY DEAN WITTER 2001 September 27
-
(2001)
Morgan Stanley Dean Witter
-
-
Rubin, J.1
Yu, N.2
Sone, T.3
-
25
-
-
0009020122
-
A phase I clinical and biomarker study of the novel pan-ErbB tyrosine kinase inhibitor, Cl-1033, in patients with solid tumors
-
Abs 566
-
A phase I clinical and biomarker study of the novel pan-ErbB tyrosine kinase inhibitor, Cl-1033, in patients with solid tumors. Zinner RG, Nemunaitis JJ, Donato NJ, Shin HC, Myers JW, Zhang PS, Zentgraft E, Lee JJ, Khuri FR, Glisson BS, Eiseman I et al AACR NCI EORTC MOL TARGETS CANCER THER 2001 Abs 566
-
(2001)
AACR NCI EORTC Mol Targets Cancer Ther
-
-
Zinner, R.G.1
Nemunaitis, J.J.2
Donato, N.J.3
Shin, H.C.4
Myers, J.W.5
Zhang, P.S.6
Zentgraft, E.7
Lee, J.J.8
Khuri, F.R.9
Glisson, B.S.10
Eiseman, I.11
-
26
-
-
33748172175
-
Radio-sensitization by pan ErbB-2 inhibitor Cl-1033 in vitro and in vivo
-
Abs 1013
-
Radio-sensitization by pan ErbB-2 inhibitor Cl-1033 in vitro and in vivo. Nyati MK, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, Leopold WR, Ethier SP, Theodore LS PROC ANNU MEET AM ASSOC CANCER RES 2002 43 Abs 1013
-
(2002)
Proc Annu Meet Am Assoc Cancer Res
, vol.43
-
-
Nyati, M.K.1
Sreekumar, A.2
Rynkiewicz, S.D.3
Chinnaiyan, A.M.4
Leopold, W.R.5
Ethier, S.P.6
Theodore, L.S.7
-
27
-
-
0002839618
-
Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-ErbB tyrosine kinase inhibitor, Cl-1033
-
Abs 58
-
Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-ErbB tyrosine kinase inhibitor, Cl-1033. Zinner RG, Donato NJ, Nemunaitis JJ, Cunningham CC, Shin HJ, Zentgraf RE, Ayers GD, Glisson BS, Khuri FR, Kies MS, Eiseman I et al PROC AM SOC CLIN ONCOL 2002 21 Abs 58
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Zinner, R.G.1
Donato, N.J.2
Nemunaitis, J.J.3
Cunningham, C.C.4
Shin, H.J.5
Zentgraf, R.E.6
Ayers, G.D.7
Glisson, B.S.8
Khuri, F.R.9
Kies, M.S.10
Eiseman, I.11
-
28
-
-
0042504781
-
American Society of Clinical Oncology - 38th Annual Meeting (Part VI) - OVERNIGHT REPORT, Orlando, FL, USA
-
May 18-21
-
American Society of Clinical Oncology - 38th Annual Meeting (Part VI) - OVERNIGHT REPORT, Orlando, FL, USA. Ertich R IDDB MEETING REPORT 2002 May 18-21
-
(2002)
IDDB Meeting Report
-
-
Ertich, R.1
-
29
-
-
0003282155
-
A population pharmacokinetic (PPK) analysis of oral Cl-1033, a pan-ErfaB tyrosine kinase inhibitor, in patients with advanced solid tumors
-
Abs 361
-
A population pharmacokinetic (PPK) analysis of oral Cl-1033, a pan-ErfaB tyrosine kinase inhibitor, in patients with advanced solid tumors. Olson SC, Baker L, Cunningham CC, Garrison MA, Shin D, Nemunaitis J, Shin HJ, Tolcher HJ, Zinner R, Eiseman I, Leneham P PROC AM SOC CLIN ONCOL 2002 21 Abs 361
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Olson, S.C.1
Baker, L.2
Cunningham, C.C.3
Garrison, M.A.4
Shin, D.5
Nemunaitis, J.6
Shin, H.J.7
Tolcher, H.J.8
Zinner, R.9
Eiseman, I.10
Leneham, P.11
-
30
-
-
0003282147
-
A phase I clinical and pharmacokinetic study of oral Cl-1033, a pan-ErbB tyrosine kinase inhibitor, in patients with advanced solid tumors
-
Abs 41
-
A phase I clinical and pharmacokinetic study of oral Cl-1033, a pan-ErbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Rinehart JJ, Wilding G, Willson J, Krishnamurthi S, Natale R, Mani S, Burnett D, Olson S, Bycott P, Owens-Grillo JK, Hes M et al PROC AM SOC CLIN ONCOL 2002 21 Abs 41 This study compared the toxicity of a variety of canertinib treatment regimens.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Rinehart, J.J.1
Wilding, G.2
Willson, J.3
Krishnamurthi, S.4
Natale, R.5
Mani, S.6
Burnett, D.7
Olson, S.8
Bycott, P.9
Owens-Grillo, J.K.10
Hes, M.11
-
31
-
-
0034853561
-
Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor Cl-1033
-
Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor Cl-1033. Gieseg MA, de Bock C, Ferguson LR, Denny WA ANTICANCER DRUGS 2001 12 8 683-690
-
(2001)
Anticancer Drugs
, vol.12
, Issue.8
, pp. 683-690
-
-
Gieseg, M.A.1
De Bock, C.2
Ferguson, L.R.3
Denny, W.A.4
-
32
-
-
0035168761
-
CM 033, a pan-erbB tyrosine kinase inhibitor
-
CM 033, a pan-erbB tyrosine kinase inhibitor. Slichenmyer WJ, Elliott WL, Fry DW SEMIN ONCOL 2001 28 5 Suppl 16 80-85
-
(2001)
Semin Oncol
, vol.28
, Issue.5 SUPPL. 16
, pp. 80-85
-
-
Slichenmyer, W.J.1
Elliott, W.L.2
Fry, D.W.3
-
33
-
-
0035256698
-
Untangling the ErbB signaling network
-
Untangling the ErbB signaling network. Yarden Y, Sliwkowski M NAT REV MOL CELL BIOL 2001 2 2 127-137
-
(2001)
Nat Rev Mol Cell Biol
, vol.2
, Issue.2
, pp. 127-137
-
-
Yarden, Y.1
Sliwkowski, M.2
-
34
-
-
33748170845
-
Signal transduction modulators in cancer therapy - First International Symposium (Part II), Amsterdam, the Netherlands
-
September 23-25
-
Signal Transduction Modulators in Cancer Therapy - First International Symposium (Part II), Amsterdam, the Netherlands. Sausville E IDDB MEETING REPORT 2002 September 23-25
-
(2002)
IDDB Meeting Report
-
-
Sausville, E.1
-
35
-
-
33748128167
-
European Society for Medical Oncology - 27th Congress (Part II), Nice, France
-
IDdb Author October 18-22
-
European Society for Medical Oncology - 27th Congress (Part II), Nice, France. IDdb Author IDDB MEETING REPORT 2002 October 18-22
-
(2002)
IDDB Meeting Report
-
-
-
36
-
-
33748131042
-
Anti-receptor signaling strategies in human neoplasia - First International Symposium, Chicago, IL, USA
-
September 19-21
-
Anti-Receptor Signaling Strategies in Human Neoplasia - First International Symposium, Chicago, IL, USA. Neel BG IDDB MEETING REPORT 2002 September 19-21
-
(2002)
IDDB Meeting Report
-
-
Neel, B.G.1
-
37
-
-
33748139597
-
Pfizer 2002 annual report: Toward a healthier world
-
Pfizer Inc February 27
-
Pfizer 2002 Annual Report: Toward a Healthier World. Pfizer Inc ANNUAL REPORT 2003 February 27
-
(2003)
Annual Report
-
-
-
38
-
-
18444404925
-
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy
-
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy. Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y EMBO J 2002 21 10 2407-2417
-
(2002)
Embo J
, vol.21
, Issue.10
, pp. 2407-2417
-
-
Citri, A.1
Alroy, I.2
Lavi, S.3
Rubin, C.4
Xu, W.5
Grammatikakis, N.6
Patterson, C.7
Neckers, L.8
Fry, D.W.9
Yarden, Y.10
-
39
-
-
33748172175
-
Radio-sensitization by pan ErbB-2 inhibitor Cl-1033 in vitro and in vivo
-
Abs 013a
-
Radio-sensitization by pan ErbB-2 inhibitor Cl-1033 in vitro and in vivo. Nyati M, Sreekumar A, Rynkiewicz SD, Chinnayan AM, Leopold WR, Ethier SP, Theodore LS PROC ANNU MEET AM ASSOC CANCER RES 2002 43 Abs 013a
-
(2002)
Proc Annu Meet Am Assoc Cancer Res
, vol.43
-
-
Nyati, M.1
Sreekumar, A.2
Rynkiewicz, S.D.3
Chinnayan, A.M.4
Leopold, W.R.5
Ethier, S.P.6
Theodore, L.S.7
-
40
-
-
0036316380
-
Potential benefits of the irreversible pan-ErbB inhibitor, Cl-1033, in the treatment of breast cancer
-
Potential benefits of the irreversible pan-ErbB inhibitor, Cl-1033, in the treatment of breast cancer. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW SEMIN ONCOL 2002 29 3 Suppl 11 11-21 This study reported preclinical and clinical data that support the use of canertinib in breast cancer patients.
-
(2002)
Semin Oncol
, vol.29
, Issue.3 SUPPL. 11
, pp. 11-21
-
-
Allen, L.F.1
Lenehan, P.F.2
Eiseman, I.A.3
Elliott, W.L.4
Fry, D.W.5
-
41
-
-
0003282147
-
A phase 1 clinical and pharmacokinetic study of oral Cl-1033, a pan-ErbB tyrosine kinase inhibitor, in patients with advanced solid tumors
-
Abs 41
-
A phase 1 clinical and pharmacokinetic study of oral Cl-1033, a pan-ErbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Rinehart JJ, Wilding G, Willson J, Krishnamurthi S, Natale R, Mani S, Olson S, Bycott P, Owens-Griilo JK, Hes M PROC AM SOC CLIN ONCOL 2002 21 Abs 41
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Rinehart, J.J.1
Wilding, G.2
Willson, J.3
Krishnamurthi, S.4
Natale, R.5
Mani, S.6
Olson, S.7
Bycott, P.8
Owens-Griilo, J.K.9
Hes, M.10
-
42
-
-
0005434961
-
A phase 1 clinical and biomarker study of the novel pan-ErbB tyrosine kinase inhibitor, Cl-1033, in patients with solid tumors
-
A phase 1 clinical and biomarker study of the novel pan-ErbB tyrosine kinase inhibitor, Cl-1033, in patients with solid tumors. Zinner RG, Nemunaitis JJ, Donato NJ, Shin HC, Myers JN, Zhang PS, Lee JJ, Khuri FR, Glisson BS CLIN CANCER RES 2001 7 3767S-3768S
-
(2001)
Clin Cancer Res
, vol.7
-
-
Zinner, R.G.1
Nemunaitis, J.J.2
Donato, N.J.3
Shin, H.C.4
Myers, J.N.5
Zhang, P.S.6
Lee, J.J.7
Khuri, F.R.8
Glisson, B.S.9
-
43
-
-
84898695639
-
Inhibition of ErbB family receptors by Cl-1033 enhances the cytotoxicity of gemcitabine via modulation of AKT and MAP kinases
-
Abs 241
-
Inhibition of ErbB family receptors by Cl-1033 enhances the cytotoxicity of gemcitabine via modulation of AKT and MAP kinases. Nelson JM, Fry DW PROC ANNU MEET AM ASSOC CANCER RES 2000 41 Abs 241
-
(2000)
Proc Annu Meet Am Assoc Cancer Res
, vol.41
-
-
Nelson, J.M.1
Fry, D.W.2
-
44
-
-
0000300539
-
Effect of epidermal growth factor receptor tyrosine kinase inhibitor PD183805 on vascular endothelial growth factor secretion from several tumor models
-
Abs 141
-
Effect of epidermal growth factor receptor tyrosine kinase inhibitor PD183805 on vascular endothelial growth factor secretion from several tumor models. Driscoll D, Steinkampf R, Patmore S, Elliott W, Klohs W PROC ANNU MEET AM ASSOC CANCER RES 1999 40 Abs 141
-
(1999)
Proc Annu Meet Am Assoc Cancer Res
, vol.40
-
-
Driscoll, D.1
Steinkampf, R.2
Patmore, S.3
Elliott, W.4
Klohs, W.5
-
45
-
-
0000299340
-
Optimal in vivo treatment schedule for the novel EGF receptor family tyrosine kinase inhibitor, PD-183805, correlates with inhibition of receptor tyrosine phosphorylation
-
Abs 776
-
Optimal in vivo treatment schedule for the novel EGF receptor family tyrosine kinase inhibitor, PD-183805, correlates with inhibition of receptor tyrosine phosphorylation. Vincent PW, Patmore SJ, Atkinson BE, Bridges AJ, Kirkish LS, Dudeck RC, Leopold WR, Zhou H, Elliott WL PROC ANNU MEET AM ASSOC CANCER RES 1999 40 Abs 776
-
(1999)
Proc Annu Meet Am Assoc Cancer Res
, vol.40
-
-
Vincent, P.W.1
Patmore, S.J.2
Atkinson, B.E.3
Bridges, A.J.4
Kirkish, L.S.5
Dudeck, R.C.6
Leopold, W.R.7
Zhou, H.8
Elliott, W.L.9
-
46
-
-
0034565927
-
Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
-
Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Rao GS, Murray S, Ethier SP INT J RADIAT ONCOL BIOL PHYS 2000 48 5 1519-1528
-
(2000)
Int J Radiat Oncol Biol Phys
, vol.48
, Issue.5
, pp. 1519-1528
-
-
Rao, G.S.1
Murray, S.2
Ethier, S.P.3
-
47
-
-
33748181280
-
Cl-1033 a pan Erb-B family tyrosine kinase inhibitor induces apoptosis in glioblastoma cells in a non-growth arrest pattern
-
Abs 778
-
Cl-1033 a pan Erb-B family tyrosine kinase inhibitor induces apoptosis in glioblastoma cells in a non-growth arrest pattern. Allen AM, Ethier SP PROC ANNU MEET AM ASSOC CANCER RES 2003 42 Abs 778
-
(2003)
Proc Annu Meet Am Assoc Cancer Res
, vol.42
-
-
Allen, A.M.1
Ethier, S.P.2
-
48
-
-
0034600849
-
The ErbB signaling network: Receptor heterodimerization in development and cancer
-
The ErbB signaling network: Receptor heterodimerization in development and cancer. Olayioye M, Neve R, Lane H, Hynes NE EMBO J 2000 19 13 3159-3167
-
(2000)
Embo J
, vol.19
, Issue.13
, pp. 3159-3167
-
-
Olayioye, M.1
Neve, R.2
Lane, H.3
Hynes, N.E.4
-
49
-
-
2142654748
-
Administration of Cl-1033, an irreversible pan-ErbB tyrsosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off schedule: A phase I, pharmacokinetic (PK), and food effect study
-
Abs 807
-
Administration of Cl-1033, an irreversible pan-ErbB tyrsosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off schedule: A phase I, pharmacokinetic (PK), and food effect study. Rowinsky EK, Garrison M, Lorusso P, Patnaik A, Hammond L, De Bono J, McCreery H, Eiseman I, Lenehan P, Tolcher A PROC AM SOC CLIN ONCOL 2003 22 Abs 807
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
-
-
Rowinsky, E.K.1
Garrison, M.2
Lorusso, P.3
Patnaik, A.4
Hammond, L.5
De Bono, J.6
McCreery, H.7
Eiseman, I.8
Lenehan, P.9
Tolcher, A.10
-
50
-
-
2142704086
-
A phase I clinical and pharmacokinetic (PK)/food effect study of oral Cl-1033, a pan-erb B tyrosine kinase inhibitor, in patients with advanced solid tumors
-
Abs 821
-
A phase I clinical and pharmacokinetic (PK)/food effect study of oral Cl-1033, a pan-erb B tyrosine kinase inhibitor, in patients with advanced solid tumors. Rinehart JJ, Wilding G, Willson J, Krishnamurthi S, Natale R, Dasse KD, Olson S, Marcy P, Lenehan P, Chakrabarti D PROC AM SOC CLIN ONCOL 2003 22 Abs 821
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
-
-
Rinehart, J.J.1
Wilding, G.2
Willson, J.3
Krishnamurthi, S.4
Natale, R.5
Dasse, K.D.6
Olson, S.7
Marcy, P.8
Lenehan, P.9
Chakrabarti, D.10
-
51
-
-
33748161941
-
American Urological Association - 98th Annual Meeting, Chicago, IL, USA
-
April 26-May 01
-
American Urological Association - 98th Annual Meeting, Chicago, IL, USA. Jamison J IDDB MEETING REPORT 2001 April 26-May 01
-
(2001)
IDDB Meeting Report
-
-
Jamison, J.1
-
52
-
-
0344773397
-
A phase 1 trial of Cl-1033, a pan-ErbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors
-
Abs 974
-
A phase 1 trial of Cl-1033, a pan-ErbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors. Nemunaitis JJ, Eiseman I, Cunningham C, Lenehan P, Olson S, Bycott P, Schlicht M, Zentgraff R, Shin D, Zinner R PROC AM SOC CLIN ONCOL 2003 22 Abs 974
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
-
-
Nemunaitis, J.J.1
Eiseman, I.2
Cunningham, C.3
Lenehan, P.4
Olson, S.5
Bycott, P.6
Schlicht, M.7
Zentgraff, R.8
Shin, D.9
Zinner, R.10
-
53
-
-
33748169436
-
Analyst meeting - Research and early development
-
Pfizer Inc June 17
-
Analyst meeting - research and early development Pfizer Inc COMPANY PRESENTATION 2003 June 17
-
(2003)
Company Presentation
-
-
-
54
-
-
0028237507
-
Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification
-
Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Ekstrand AJ, Longon N, Hamid ML, Olson JJ, Liu L, Collins VP ONCOGENE 1994 9 8 2313-2320
-
(1994)
Oncogene
, vol.9
, Issue.8
, pp. 2313-2320
-
-
Ekstrand, A.J.1
Longon, N.2
Hamid, M.L.3
Olson, J.J.4
Liu, L.5
Collins, V.P.6
-
55
-
-
0028859415
-
Effect of endogenous and exogenous EGF on the growth of EGF receptor-hyperproducing human squamous cell carcinoma implanted in nude mice
-
Effect of endogenous and exogenous EGF on the growth of EGF receptor-hyperproducing human squamous cell carcinoma implanted in nude mice. Kitagawa Y, Ueda M, Ando N, Ozawa S, Kitajima M BR J CANCER 1995 72 4 865-868
-
(1995)
Br J Cancer
, vol.72
, Issue.4
, pp. 865-868
-
-
Kitagawa, Y.1
Ueda, M.2
Ando, N.3
Ozawa, S.4
Kitajima, M.5
-
56
-
-
0034234854
-
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ublquitination of HER-2
-
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ublquitination of HER-2. Klapper L, Waterman H, Sela M, Yarden Y CANCER RES 2000 60 13 3384-3388
-
(2000)
Cancer Res
, vol.60
, Issue.13
, pp. 3384-3388
-
-
Klapper, L.1
Waterman, H.2
Sela, M.3
Yarden, Y.4
-
57
-
-
0032445260
-
HER-2/neu as a predictive marker of response to breast cancer therapy
-
HER-2/neu as a predictive marker of response to breast cancer therapy. Pegram MD, Pauletti G, Slamon DJ BREAST CANCER RES TREAT 1998 52 1-3 65-77
-
(1998)
Breast Cancer Res Treat
, vol.52
, Issue.1-3
, pp. 65-77
-
-
Pegram, M.D.1
Pauletti, G.2
Slamon, D.J.3
-
58
-
-
0025831844
-
Expression of mutant p53, c-ErbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder
-
Expression of mutant p53, c-ErbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CH, Neal DE BR J CANCER 1991 63 6 967-970
-
(1991)
Br J Cancer
, vol.63
, Issue.6
, pp. 967-970
-
-
Wright, C.1
Mellon, K.2
Johnston, P.3
Lane, D.P.4
Harris, A.L.5
Horne, C.H.6
Neal, D.E.7
-
59
-
-
33748141337
-
Annual research report for 1998
-
University of Auckland December 31
-
Annual research report for 1998. University of Auckland ANNUAL REPORT 1998 December 31
-
(1998)
Annual Report
-
-
|